Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study

BACKGROUND: Sorafenib was approved for treatment of unresectable hepatocellular carcinoma (HCC) in Japan in 2009. A prospective postmarketing all-patient surveillance (PMS) study was requested by Japanese authorities to confirm safety and effectiveness of sorafenib in Japanese HCC population. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneko, Shuichi, Ikeda, Kenji, Matsuzaki, Yasushi, Furuse, Junji, Minami, Hironobu, Okayama, Yutaka, Sunaya, Toshiyuki, Ito, Yuichiro, Inuyama, Lyo, Okita, Kiwamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037148/
https://www.ncbi.nlm.nih.gov/pubmed/26931117
http://dx.doi.org/10.1007/s00535-016-1173-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5037148/
https://www.ncbi.nlm.nih.gov/pubmed/26931117
http://dx.doi.org/10.1007/s00535-016-1173-5

Ejemplares similares